结果与未治疗相比，Molnupiravir与30天（相对风险0.72（95％置信区间0.64至0.79））的住院或死亡减少有关； 30天的住院或死亡的事件发生率为2.7％（95％的置信区间2.5％至3.0％），无治疗方法为3.8％（3.7％至3.9％）；绝对风险降低为1.1％（95％置信区间0.8％至1.4％）。Molnupiravir appeared to be effective in those who had not been vaccinated against covid-19 (relative risk 0.83 (0.70 to 0.97) and absolute risk reduction 0.9% (0.2% to 1.9%)), had received one or two vaccine doses (0.69 (0.56 to 0.83) and 1.3% (0.7% to 1.9%)), and had received a booster dose (0.71 (0.58至0.83）和1.0％（0.5％至1.4％））;在那些在OMICROR子体BA.1或BA.2的时代被感染的人中，主要是（0.72（0.72至0.62至0.83）和1.2％（0.7％至1.6％）），而BA.5占主导地位（0.75（0.75（0.75）（0.75（0.66至0.86）和0.9％至0.9％至1.3％至1.3％）；在没有SARS-COV-2感染史（0.72（0.64至0.81）和1.1％（0.8％至1.4％）的患者中，并且有SARS-COV-2感染史（0.75（0.58至0.97）和1.1％（0.1％（0.1％至1.8％）））。